Maurizio Luongo, Chief Executive Officer of Menarini Asia-Pacific

Mr. Luongo is Chief Executive Officer (CEO) of Menarini Asia-Pacific. A member of the Menarini Group, Menarini Asia-Pacific has a direct presence in 13 markets with over 3,500 employees and strives to be a leading provider that invigorates lives. With robust R&D and manufacturing prowess, Menarini Asia-Pacific operates across the entire commercial value chain with a diverse portfolio of proprietary and partnered brands from Consumer Health to Dermatology, Allergy/Respiratory, Gastroenterology, Cardio-metabolic, Anti-infectives, Oncology/Specialty Care and Men’s Health.

Since joining the group in 2010, Mr. Luongo has significantly grown Menarini’s operations and Consumer Health business. He has served in various capacities as the Corporate Director of Consumer Health, Chief Operating Officer, and since 2019 as the CEO of Menarini Asia-Pacific. As CEO of Menarini Asia-Pacific, Mr. Luongo has leveraged the company’s deep European roots to deliver innovative healthcare offerings to the region, with a number of significant partnership and licencing deals secured. Within a year of being appointed CEO, he led the company to achieve unprecedented EBITA growth of 247% increase from 2020 to 2021.

As CEO of Menarini Asia-Pacific, Mr. Luongo is responsible for driving the distribution expansion of Menarini’s portfolio in the region. Notable milestones include Menarini’s acquisition of Cialis® in 2021 – strengthening its Men’s Health portfolio, now a top three player in this therapeutic area and earning Menarini the 100-Million Digital Brand of the Year Award from Alibaba Health Pharmacy in China; an exclusive licensing agreement with Daiichi Sankyo to sell, market and distribute Tarlige® in Singapore, Malaysia and Philippines – expanding Menarini’s established portfolio of pain products; and the recently announced exclusive licensing agreement with SciClone Pharmaceuticals to develop and commercialize Vaborem® in China – addressing the unmet need in antimicrobial resistant infections.

Mr. Luongo’s understanding of the great potential that diagnostics bring to patients led him to facilitate a novel partnership between Menarini Biomarkers, the company’s diagnostic arm, and KK Women’s and Children’s Hospital and SingHealth Duke-NUS Maternal and Child Health Research Institute, to launch a new Asia research institute for healthcare biotechnology and diagnostics. Focusing on maternal and child health, the hub is the first-of-its-kind outside Europe, tackling genetic disorders through non-invasive diagnostics in prenatal and targeted therapies.

Mr. Luongo’s innovative spirit continues to drive Menarini’s transformation as a global biopharmaceutical company, expanding distribution strategies beyond traditional pharmaceutical channels to e-commerce platforms. In addition to bolstering the region’s distribution platforms and its omni-channel strategy, Mr. Luongo is also overseeing the expansion of manufacturing facilities in South East Asia to meet growing future demand and offer partners more capabilities in the region.

Mr. Luongo translates his passion for patient-centricity into action, transforming Menarini Asia-Pacific into the biopharmaceutical provider of choice that can ensure undisrupted access to medicines to populations in the region. In all his roles, Mr. Luongo has proven himself to be a compassionate and inclusive leader, who is highly attuned to market needs and passionate about healthcare equity.

Prior to joining Menarini, Mr. Luongo held various business and leadership roles in L’Oreal, Tigi Italia Health and Angelini Pharma. Mr. Luongo graduated with an MBA from Stoà Institute in cooperation with MIT and has a bachelor’s degree in Business Administration and Economics from Salerno University.